A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.

PURPOSE Anaplastic thyroid cancer (ATC) has poor prognosis with median overall survival ~6 months. We previously reported high PD-1/PDL-1 staining in ATC, raising the possibility of the productive application of the immunotherapeutic pembrolizumab. However, having found pembrolizumab to anecdotally have limited single-agent activity in ATC, we sought to alternatively define whether pembrolizumab might synergistically combine with chemoradiotherapy as initial ATC therapy. PATIENT AND METHODS An investigator-initiated therapeutic phase 2 trial of pembrolizumab, 200 mg IV every 3 weeks, combined with chemoradiotherapy [docetaxel/doxorubicin, 20 mg/m2 each IV weekly plus volumetric modulated arc therapy (VMAT)] was initiated as front-line therapy (with or without surgery) in ATC to assess efficacy and toxicities. Six-month overall survival (OS) was selected as the primary endpoint using a Simon's optimal design with interim analysis (targeting accrual of 25 patients; Cohort A: prior resection, Cohort B: no resection). Based upon a prior patient cohort treated similarly, but without pembrolizumab, the design was such that, if 6 month true survival is 75%, the probability of declaring the approach worthy of further pursuit would be 91%. RESULTS Three patients were enrolled, two with rapidly enlarging unresectable neck masses. Early tumor responses were favorable in all three, and all three satisfactorily completed: intended radiotherapy, preceding and radiotherapy-concurrent pembrolizumab, and concurrent chemoradiotherapy. However, all three patients died <6 months following therapy initiation - one from pulmonary metastases, and two from otherwise unexpected fatal pulmonary complications occurring subsequent to chemoradiotherapy completion - prompting study closure. CONCLUSION Although initially tolerated and effective in terms of locoregional disease control, disappointing survival outcomes compared to historical controls raise uncertainty that the piloted approach merits further pursuit in ATC.

[1]  C. Lin,et al.  Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. , 2018, Chest.

[2]  A. Garden,et al.  Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. , 2018, Thyroid : official journal of the American Thyroid Association.

[3]  M. Rivera,et al.  Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer , 2017, The Journal of clinical endocrinology and metabolism.

[4]  G. Weiss,et al.  A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus) , 2017, British Journal of Cancer.

[5]  J. Kasperbauer,et al.  Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study , 2017, The Journal of clinical endocrinology and metabolism.

[6]  A. Garden,et al.  Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base , 2017, Cancer.

[7]  S. Devesa,et al.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 , 2017, JAMA.

[8]  Tae Yong Kim,et al.  Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area. , 2016, Thyroid : official journal of the American Thyroid Association.

[9]  R. McIntyre,et al.  Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. , 2016, The Journal of clinical endocrinology and metabolism.

[10]  S. Mane,et al.  Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.

[11]  J. Shah,et al.  Anaplastic Thyroid Carcinoma: A 25-year Single-Institution Experience , 2014, Annals of Surgical Oncology.

[12]  R. Smallridge,et al.  Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. , 2011, Thyroid : official journal of the American Thyroid Association.

[13]  J. Hay,et al.  Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  E. Baudin,et al.  Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. , 2004, International Journal of Radiation Oncology, Biology, Physics.

[15]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.